Genfit Delays NASH Data While It Confers With US FDA On Methodology

 
• By Joseph Haas
  
Data Collection - Three Arrows Hit in Red Target
Genfit will await FDA insight on statistical methodology before unblinding its Phase III NASH study
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D